Toggle navigation
TWunroll
TWunroll
faq
Contact US
James Krellenstein
jbkrell
I am a little confused by this @nytimes reporting by @MarcSantoraNYT and @RebeccaDRobbins on the new AZD1222 data. First of all, the claim that this data is the “first” to
Read more
The @Dereklowe piece sort of misses the point. Yes, there is no idle mRNA vaccine production capacity in the pharma industry that could simply be repurposed to make more COVID-19
Read more
So the @Novavax results showing 90% vs. 49% efficacy make the results of the @JNJNews results even more exciting. JNJ is evaluating their Ad26 vaccine in S Africa as
Read more
When I was 22, I watched a friend become HIV+ cuz he couldn't afford Truvada PrEP which cost s$1,300/m but costs
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our
Cookie Policy
to improve your experience.
I agree